Cite
MLA Citation
Y-L Wu et al.. “339TiPPACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC.” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100098039198.0x000032